Vericel Corporation

VCEL | NASDAQ

Price Alert Chart Builder DCF Calculator

$39.75

+$0.20 (+0.51%)

Sep 22, 2026, 11:06 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.51%

(1D)

Rating

Updated: Aug 19, 2026

59.6

Fundamentals Strong

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $2.04B

1D Range

39.54 40.28

52W Range

28.95 49.32

Valuation (TTM)

PE 84.15

PB 5.47

EV/EBITDA 50.85

Valuation (NTM)

Forward PE 44.44

Forward PEG 1.33

Price Target $61.33

Cash Flow

FCF Yield 2.5%

SBC Adj. FCF Yield 1.6%

SBC Impact -34.5%

Margins

Gross Margin 74.6%

Operating Margin 6.0%

FCF Margin 16.2%

Growth (CAGR)

Revenue 3Y | 5Y 19.8% | 15.1%

Dil EPS 3Y | 5Y 116.4% | 21.2%

FCF 3Y | 5Y 54.4% | 14.8%

Returns

ROA 4.8%

ROE 6.9%

ROIC 3.8%

Financial Health

Net Cash

$69.92M

Current Ratio 5.04

Interest Coverage 28.49

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments....

Sector Healthcare

Industry Biotechnology

Employees 398

IPO Date Feb 3, 1997

Website vcel.com

Fiscal Year January - December

Full Company Profile

Latest News

6 days ago · seekingalpha.com

Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

8 days ago · seekingalpha.com

Vericel: MACI And Regenerative Knee Cartilage

Vericel's MACI already has an established commercial base, which I think gives them an easier path for future growth. MACI's arthroscopic delivery could also help it expand among surgeons. That's why VCEL's Burlington added capacity is timely if demand indeed increases. I also like that VCEL's recently gained BARDA contract helps with its Burn Care business. VCEL also has a potential UK launch and an ankle indication in the works.

14 days ago · globenewswire.com

Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026

BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15th, 2026.

2 months ago · marketbeat.com

Vericel Q2 Earnings Call Highlights

Vericel NASDAQ: VCEL reported record second-quarter revenue and raised its full-year outlook, citing continued growth in its MACI cartilage repair franchise and Burn Care business, along with improved profitability and cash generation.

2 months ago · seekingalpha.com

Vericel Corporation (VCEL) Q2 2026 Earnings Call Transcript

2 months ago · zacks.com

Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates

Vericel Corporation (VCEL) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to a loss of $0.01 per share a year ago.

2 months ago · globenewswire.com

Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program

Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Million Board of Directors Authorizes $200 Million Share Repurchase Program Conference Call Today at 8:30am Eastern Time BURLINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2026.

2 months ago · globenewswire.com

Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026

BURLINGTON, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second quarter 2026 financial results on Thursday, July 30, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

4 months ago · globenewswire.com

Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026

BURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16th, 2026.